Maxim analyst Jason McCarthy upgraded Reviva Pharmaceuticals (RVPH) to Buy from Hold with a $7 price target
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVPH:
- Reviva Pharmaceuticals initiated with a Buy at Roth MKM
- Reviva Pharmaceuticals Strengthens Financial Position with Offering
- Reviva Pharmaceuticals 12M share Spot Secondary priced at $1.50
- Reviva Pharmaceuticals announces common stock, warrant offering, no amount given
- Reviva Pharmaceuticals Reports Positive Phase 3 Trial Results